Symberix

Symberix is pioneering a novel class of microbiome-sparing therapeutics by developing small molecules that inhibit specific bacterial enzymes linked to disease, rather than killing bacteria outright. This strategy seeks to treat conditions like inflammatory diseases and mitigate antibiotic side effects without contributing to antimicrobial resistance or dysbiosis. The company is advancing a pipeline of preclinical candidates, leveraging its proprietary discovery platform to identify bacterial enzyme targets and design selective inhibitors. As a private, preclinical-stage biotech, Symberix represents a targeted investment in the next generation of microbiome modulation.

Proprietary platform for discovering selective small-molecule inhibitors of specific bacterial enzymes in the gut microbiome, designed to treat disease without killing bacteria or disrupting microbial ecology.

Symberix competes with a range of microbiome-focused companies, including those developing live biotherapeutics (e.g., Seres, Vedanta), phage therapies, and other small-molecule modulators. Its key differentiation is the explicit goal of sparing the microbiome via enzyme-specific inhibition, rather than altering microbial composition.